Solvonis TherapeuticsLSE:SVNS -1.82% Market Cap is £11.03 Mil as of Jul. 12, 2026. The stock has 4 warning signs investors should review. Among 3,095 Industrial Products companies, Solvonis Therapeutics ranks worse than 88.43% on this metric.
Solvonis Therapeutics's quarterly market cap
increased
from Dec. 2024 (£4.71 Mil) to Jun. 2025 (£14.18 Mil) and
increased
from Jun. 2025 (£14.18 Mil) to Dec. 2025 (£21.10 Mil).
Solvonis Therapeutics's annual market cap
increased
from Dec. 2023 (£0.60 Mil) to Dec. 2024 (£4.71 Mil) and
increased
from Dec. 2024 (£4.71 Mil) to Dec. 2025 (£21.10 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Solvonis Therapeutics's Enterprise Value for Today is £9.38 Mil.
Solvonis Therapeutics (LSE:SVNS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solvonis Therapeutics Market Cap vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Solvonis Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Solvonis Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solvonis Therapeutics (LSE:SVNS) has a Market Cap of £11.03 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #2737 out of 3095 companies in the Industrial Products industry, placing it in the top 88.4%.
Is Solvonis Therapeutics' Market Cap too high?
Solvonis Therapeutics' current Market Cap is £11.03 Mil. Based on the distribution chart, Solvonis Therapeutics ranks #2737 out of 3095 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' Market Cap compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #2737 out of 3095 companies for Market Cap. This places Solvonis Therapeutics in the lower half of its industry. The industry median Market Cap is 277.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for an Industrial Products company?
The median Market Cap among Industrial Products companies is 277.98, based on 3,095 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median Market Cap is 277.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current Market Cap is £11.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (LSE:SVNS) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.00 — trading 91.9% below its estimated fair value. The current Market Cap is £11.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Solvonis Therapeutics (LSE:SVNS), the current Market Cap is £11.03 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SVNS has been successfully added to your 